Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below
      Prescribing Information
      GB SUMMARY OF PRODUCT CHARACTERISTICS
      NI SUMMARY OF PRODUCT CHARACTERISTICS

      PRODUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1,2

       

      Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
      Prescribing Information
      GB SUMMARY OF PRODUCT CHARACTERISTICS
      NI SUMMARY OF PRODUCT CHARACTERISTICS

      PRODUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1,2

      Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.

      Some patients may not be suitable for PRODUODOPA. You are strongly advised to read the Prescribing information (PI), and Summary of Product Characteristics (SmPC) for Great Britain (GB) or Northern Ireland (NI) which can be found via the links above, to evaluate patient suitability for PRODUODOPA.

      Contact us

      Please complete the form below and a member of the PRODUODOPA team will get back to you.

      Please fill in your details below only if you are a UK registered healthcare professional and would like to request a meeting with an AbbVie representative.

      Please enter First name
      Please enter Last name
      E-mail address is not valid
      Please enter Hospital name
      Please enter Hospital postcode
      Request a meeting with your local AbbVie representative
      Please select one field.


      Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

      *Denotes mandatory field

      Incorrect. Please try again.

      Please refer to the PRODUODOPA Summary of Product Characteristics (SmPC) for further information on adverse events, contraindications and special warnings and precautions for use.

      References

      1. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) GB Summary of Product Characteristics.
      2. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) NI Summary of Product Characteristics.
      PRODUODOPA PRESCRIBING INFORMATION

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected]

      UK-PRODD-230058. Date of preparation: December 2023.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.